GENETIC POLYMORPHISMS IN DOPAMINERGIC SYSTEM AND TREATMENT-RESISTANT SCHIZOPHRENIA
| Autor: | Tea, Terzić, Matej, Kastelic, Vita, Dolžan, Blanka Kores, Plesničar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Genotype Receptors Dopamine D2 Receptors Dopamine D1 Receptors Dopamine D3 Middle Aged Catechol O-Methyltransferase Polymorphism Single Nucleotide dopamine COMT - single nucleotide polymorphism treatment-resistant schizophrenia antipsychotic Pharmacogenetics Schizophrenia Humans Female Antipsychotic Agents |
| Zdroj: | Psychiatria Danubina Volume 28 Issue 2 |
| ISSN: | 0353-5053 |
| Popis: | Background: Dopaminergic system plays an important role in antipsychotic response. Functional single nucleotide polymorphisms (SNPs) can change dopamine receptor expression or dopamine disposition and thus influence response to antipsychotic treatment. Subjects and methods: 138 schizophrenia patients were stratified in the treatment-resistant and treatment-responsive group. Control group consisted of 94 healthy blood donors. All subjects were genotyped for the following SNPs: DRD1 (rs4532, rs5326), DRD2 (rs1801028, rs1799732), DRD3 (rs6280) and COMT (rs165815, rs4680). Association between the genotypes and clinical symptoms were tested using ANCOVA with current antipsychotic dose as a confounder. Differences in allele frequencies between treatment-responsive and treatment-resistant schizophrenic patients were assessed using χ2 tests. Results: No statistically significant associations were observed between any of the investigated genotypes and clinical scores and occurrence of the treatment-resistant schizophrenia. Conclusions: Genetic variability in dopaminergic system does not have a major role in clinical symptoms and occurrence of treatment-resistant schizophrenia among Slovenian patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|